The FDA issued an emergency use authorization for Novavax’s two-dose COVID-19 vaccine, making it the fourth COVID-19 vaccine available for use in the United States.
The FDA said the vaccine “has met the statutory criteria” for an emergency use authorization (EUA) for people aged 18 years or older and that data show the benefits of the vaccine outweigh its risks.
“Authorizing an additional COVID-19 vaccine expands the available vaccine options for the prevention of COVID-19, including the most severe outcomes that can occur such as hospitalization and death,” FDA